NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical results from multiple in vitro studies targeting alpha-synuclein (α-synuclein), specifically the A53T mutation, that demonstrate the compounds' potential to advance the treatment of Parkinson's Disease (PD). The compounds may be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs, Inc. (Aexon Labs or AEX).
"These in vitro results obtained from various Aexon Labs preclinical compounds, discovered through our next-generation non-sulfonamide dual orexin agonist (DOXA) platform, show promising insights to help us further the development of potentially differentiated and more effective treatments for patients living with PD," said Alex Zwyer, Chief Executive Officer of NLS.
Using the "Alpha-Synuclein (α-synuclein) A53T Parkinson's Disease Genetic Cell-Based Agonist Neurite Outgrowth Assay" by Eurofins, various DOXA compounds demonstrated positive effects on neurite outgrowth, a critical parameter of neuronal health and regeneration.
Neurite outgrowth, a critical parameter of neuronal health, was measured using high-content imaging systems to determine the efficacy of AEX compounds. Reducing α-synuclein aggregation or promoting its clearance can alleviate its toxic effects on neurons. The effects of AEX compounds on neurite outgrowth as well as their impact on Cathepsin D (CTSD) and Orexin 1 Receptor (OX1R) activities provide insights into their potential to modulate the impact of α-synuclein.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.